Your browser doesn't support javascript.
loading
Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer.
Arai, Jun; Otoyama, Yumi; Fujita, Ken-Ichi; Goto, Kaku; Tojo, Masayuki; Katagiri, Atsushi; Nozawa, Hisako; Kubota, Yutaro; Takahashi, Takehiro; Ishida, Hiroo; Tsunoda, Takuya; Matsumoto, Natsumi; Ogawa, Keita; Nakagawa, Ryo; Muroyama, Ryosuke; Kato, Naoya; Yoshida, Hitoshi.
Afiliação
  • Arai J; Division of Gastroenterology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, Japan. araiguma10@med.showa-u.ac.jp.
  • Otoyama Y; Division of Gastroenterology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, Japan.
  • Fujita KI; Division of Cancer Genome and Pharmacotherapy, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan.
  • Goto K; Institut de Recherche Sur Les Maladies Virales Et Hépatiques, INSERM, Strasbourg, France.
  • Tojo M; Division of Gastroenterology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, Japan.
  • Katagiri A; Division of Gastroenterology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, Japan.
  • Nozawa H; Division of Gastroenterology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, Japan.
  • Kubota Y; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
  • Takahashi T; Division of Medical Oncology, Showa University Fujigaoka Hospital, Yokohama, Japan.
  • Ishida H; Division of Internal Medicine, Department of Medicine, Showa University Hokubu Hospital, Yokohama, Japan.
  • Tsunoda T; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
  • Matsumoto N; Division of Cancer Genome and Pharmacotherapy, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan.
  • Ogawa K; Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Nakagawa R; Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Muroyama R; Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Kato N; Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Yoshida H; Division of Gastroenterology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, Japan.
BMC Cancer ; 22(1): 428, 2022 Apr 20.
Article em En | MEDLINE | ID: mdl-35443621
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Antígenos de Histocompatibilidade Classe I Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Antígenos de Histocompatibilidade Classe I Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article